Lipid IVa (High Purity Precursor of LPS)

<strong>Lipid IVa (High Purity)</strong>_x000D_ <strong>Catalog number:</strong> MDP0892_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 0.1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 1405.7 g/mol_x000D_ <strong>Supplied as:</strong> Neat_x000D_ <strong>Applications:</strong> biosynthetic precursor of Lipopolysaccharides (LPS)_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> lipid IV(A), Lipid A disaccharide bisphosphate, 2,3,2'3'-Tetrakis(3-hydroxytetradecanoyl)-D-glucosaminyl-1,6-beta-D-glucosamine 1,4'-bisphosphate, 2,3,2'3'-Tetrakis(beta-hydroxymyristoyl)-D-glucosaminyl-1,6-beta-D-glucosamine 1,4'-bisphosphate_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ <strong>Indication for Use:</strong>This product is for Research Use Only. This product is NOT for human or animal use._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, Hu L, Shao F. Inflammatory_x000D_ caspases are innate immune receptors for intracellular LPS. Nature. 2014 Oct_x000D_ 9;514(7521):187-92._x000D_ _x000D_ 2: Scior T, Alexander C, Zaehringer U. Reviewing and identifying amino acids of_x000D_ human, murine, canine and equine TLR4 / MD-2 receptor complexes conferring_x000D_ endotoxic innate immunity activation by LPS/lipid A, or antagonistic effects by_x000D_ Eritoran, in contrast to species-dependent modulation by lipid IVa. Comput_x000D_ Struct Biotechnol J. 2013 Apr 5;5:e201302012._x000D_ _x000D_ 3: Ogura N, Muroi M, Sugiura Y, Tanamoto K. Lipid IVa incompletely activates_x000D_ MyD88-independent Toll-like receptor 4 signaling in mouse macrophage cell lines._x000D_ Pathog Dis. 2013 Apr;67(3):199-205._x000D_ _x000D_ 4: Bowen WS, Gandhapudi SK, Kolb JP, Mitchell TC. Immunopharmacology of lipid A_x000D_ mimetics. Adv Pharmacol. 2013;66:81-128._x000D_ _x000D_ 5: Saitoh S, Akashi S, Yamada T, Tanimura N, Kobayashi M, Konno K, Matsumoto F,_x000D_ Fukase K, Kusumoto S, Nagai Y, Kusumoto Y, Kosugi A, Miyake K. Lipid A_x000D_ antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like_x000D_ receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol._x000D_ 2004 Jul;16(7):961-9._x000D_ _x000D_ 6: Takasawa K, Kano R, Maruyama H, Hasegawa A, Kamata H. The antagonist activity_x000D_ of lipid IVa on the stimulation by lipid A of TNF-alpha production from canine_x000D_ blood mononuclear cells. Vet Immunol Immunopathol. 2011 Sep 15;143(1-2):167-9._x000D_ _x000D_ 7: Kovach NL, Yee E, Munford RS, Raetz CR, Harlan JM. Lipid IVA inhibits_x000D_ synthesis and release of tumor necrosis factor induced by lipopolysaccharide in_x000D_ human whole blood ex vivo. J Exp Med. 1990 Jul 1;172(1):77-84._x000D_ _x000D_ 8: Muroi M, Tanamoto K. Structural regions of MD-2 that determine the agonist-_x000D_ antagonist activity of lipid IVa. J Biol Chem. 2006 Mar 3;281(9):5484-91._x000D_ _x000D_ 9: Resman N, Oblak A, Gioannini TL, Weiss JP, Jerala R. Tetraacylated lipid A_x000D_ and paclitaxel-selective activation of TLR4/MD-2 conferred through hydrophobic_x000D_ interactions. J Immunol. 2014 Feb 15;192(4):1887-95._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/24688739/">10: Scior T, Lozano-Aponte J, Figueroa-Vazquez V, Yunes-Rojas JA, Zähringer U,_x000D_ Alexander C. Three-dimensional mapping of differential amino acids of human,_x000D_ murine, canine and equine TLR4/MD-2 receptor complexes conferring endotoxic_x000D_ activation by lipid A, antagonism by Eritoran and species-dependent activities_x000D_ of Lipid IVA in the mammalian LPS sensor system. Comput Struct Biotechnol J._x000D_ 2013 Aug 8;7:e201305003. </a>_x000D_ _x000D_ <strong>Products Related to Lipid IVa (High Purity)</strong> <a href="https://moleculardepot.com/product-category/Peptides/">: Peptides</a>